Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of$2.97, an Increase of 12.1 Percent; These Results Include an Unfavorable Impact of 0.42 Per Share Related to Acquired IPR&D and Milestones Expense   Delivers Second-Quarter Net Revenues of 15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis  Second-Quarter Global Net Revenues from the Immunology Portfolio Were $7.631 Billion, an Increase of 9. ...